ROCKVILLE, Md., March 8, 2012 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) announced today the appointment of Mr. John A. Herrmann III to the position of Vice President and General Counsel. Mr. Herrmann will have responsibility for the legal affairs of the company and will continue as its corporate secretary.
Mr. Herrmann joined Novavax in April 2010 as its Executive Director of Legal Affairs and Corporate Secretary with significant experience as an executive and in-house attorney. Prior to joining Novavax, he was Vice President and General Counsel of Ore Pharmaceuticals, formerly known as Gene Logic. Before Gene Logic, Mr. Herrmann held senior level in-house counsel positions with Celera Genomics and Baxter Healthcare. At Celera, he was responsible for implementing the founder subscription agreements accessing Celera's ground-breaking human genome databases. During his tenure at Baxter, he was lead counsel in the development and operation of a renal disease management affiliate that pioneered healthcare management to patients requiring dialysis in the United States. Mr. Herrmann received a bachelor's degree in history and political science from Brown University and his JD from the University of Illinois, College of Law.
"I am very pleased to announce John's promotion to Vice President and General Counsel. John has worked closely with me, our management team and the board of directors during his time here and has consistently earned the respect and admiration of his colleagues. He has played an integral role in the award of our contract from the U.S. Department of Health and Human Services, Biomedical Advanced Research and Development Authority (BARDA), the establishment of our alliance with LG Life Sciences, and, most recently, in the acquisition of our new leased-facilities at our Gaithersburg campus. We all wish John success in his future endeavors here at Novavax," commented Stanley C. Erck, President and CEO.
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using innovative virus-like particle (VLP) and recombinant nanoparticle vaccine technology, combined with new and efficient manufacturing approaches, the company produces potent vaccine candidates to combat diseases, with the goal of allowing countries to better prepare for and more effectively respond to rapidly spreading infections. Novavax is committed to using its technology platforms to create geographic-specific vaccine solutions and is therefore involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India and LG Life Sciences of Korea. Together, these companies have worldwide commercialization capacity and the global reach to create real and lasting change in the biopharmaceutical field. Additional information about Novavax is available on the company's website: www.novavax.com.
CONTACT: Frederick W. Driscoll
VP, Chief Financial Officer and Treasurer